J. Cramer

发表

3-(4-Chloro-2-Morpholin-4-yl-Thiazol-5-yl)-8-(1-Ethylpropyl)-2,6-Dimethyl-Imidazo[1,2-b]Pyridazine: A Novel Brain-Penetrant, Orally Available Corticotropin-Releasing Factor Receptor 1 Antagonist with Efficacy in Animal Models of Alcoholism

P. Hipskind, D. McKinzie, C. Hamdouchi, 2007, The Journal of Neuroscience.

In Vitro Evaluation of Novel Nitazoxanide Derivatives against Mycobacterium tuberculosis

P. Hipskind, M. Files, T. Parish, 2017, ACS omega.

Synthesis and SAR of novel histamine H3 receptor antagonists.

P. Hipskind, C. Lindsley, D. Sindelar, 2006, Bioorganic & medicinal chemistry letters.

Bactericidal Activity of an Imidazo[1, 2-a]pyridine Using a Mouse M. tuberculosis Infection Model

Marvin J. Miller, J. Cramer, Yong Cheng, 2014, PloS one.

The N- and ringhydroxylation of 2-acetylaminofluorene during carcinogenesis in the rat.

J. Miller, E. Miller, J. Cramer, 1960, Cancer research.

Identification of Phenoxyalkylbenzimidazoles with Antitubercular Activity.

P. Hipskind, M. Files, T. Parish, 2015, Journal of medicinal chemistry.

Preclinical characterization of 2-[3-[3-[(5-ethyl-4'-fluoro-2-hydroxy[1,1'-biphenyl]-4-yl)oxy]propoxy]-2-propylphenoxy]benzoic acid metabolism: in vitro species comparison and in vivo disposition in rats.

K. Cassidy, E. Perkins, D. A. Jackson, 2003, Drug metabolism and disposition: the biological fate of chemicals.

S. Hunt, D. Hommer, D. Economidou, 2009, Alcohol.

Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and Nanomolar Activity Against Mycobacterium tuberculosis.

P. Hipskind, T. Parish, H. Boshoff, 2013, ACS medicinal chemistry letters.

Imidazo[1,2-a]Pyridine-3-Carboxamides Are Active Antimicrobial Agents against Mycobacterium avium Infection In Vivo

S. Franzblau, Marvin J. Miller, Jeff S. Schorey, 2016, Antimicrobial Agents and Chemotherapy.

N-Hydroxylation: A new metabolic reaction observed in the rat with the carcinogen 2-acetylaminofluorene.

J. Miller, E. Miller, J. Cramer, 1960, The Journal of biological chemistry.

The hydroxylation of the carcinogen 2-acetylaminofluorene by rat liver: stimulation by pretreatment in vivo with 3-methylcholanthrene.

J. Miller, E. Miller, J. Cramer, 1960, The Journal of biological chemistry.

Synthesis and biological evaluation of aryl-oxadiazoles as inhibitors of Mycobacterium tuberculosis

A. Korkegian, K. Chibale, T. Parish, 2018, Bioorganic & medicinal chemistry letters.

Central H3R activation by thioperamide does not affect energy balance

D. Sindelar, M. Shepperd, J. Cramer, 2004, Pharmacology Biochemistry and Behavior.

In Vivo Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life

D. Holtzman, S. Paul, J. Cirrito, 2003, The Journal of Neuroscience.

Advancement of Imidazo[1,2-a]pyridines with Improved Pharmacokinetics and nM Activity vs. Mycobacterium tuberculosis

P. Hipskind, T. Parish, H. Boshoff, 2013 .

The synthesis and evaluation of triazolopyrimidines as anti-tubercular agents

A. Korkegian, P. Hipskind, P. Ornstein, 2017, Bioorganic & medicinal chemistry.

Synthesis and evaluation of the 2,4-diaminoquinazoline series as anti-tubercular agents.

P. Hipskind, J. Sacchettini, T. Ioerger, 2014, Bioorganic & medicinal chemistry.

Barbiturate inhibition of growth and of synthesis of deoxyribonucleic acid, ribonucleic acid and protein in cultured mammalian cells.

J. W. Cramer, J. Cramer, P. L. Whyatt, 1973, Biochemical pharmacology.

5-iodo-2'-deoxyuridine and DNA synthesis in mammalian cells.

N. Morris, J. Cramer, 1968, Experimental cell research.

DNA synthesis by mammalian cells inhibited in culture by 5-lodo-2'-deoxyuridine.

N. Morris, J. Cramer, 1966, Molecular pharmacology.

Studies on the biochemical pharmacology of 5-iodo-2'-deoxycytidine in vitro and in vivo.

W. Prusoff, J. Cramer, C. V. von Essen, 1962, Biochemical pharmacology.

5-Bromo-2'-deoxycytidine (BCDR). I. Studies on metabolism in vitro and in mice.

W. Prusoff, J. Cramer, M. Chu, 1961, Biochemical pharmacology.

5-Bromo-2'-deoxycytidine (BCDR). II. Studies with murine neoplastic cells in culture and in vitro.

W. Prusoff, J. Cramer, A. D. Welch, 1961, Biochemical pharmacology.

Synthesis and Pharmacological Characterization of 2-(2,6-dichlorophenyl)-1-((1S,3R)-5-(3-hydroxy-3-methylbutyl)-3-(hydroxymethyl)-1-methyl-3,4-dihydroisoquinolin-2(1H)-yl)ethan-1-one (LY3154207), a potent, subtype selective, and orally available positive allosteric modulator of the human dopamine D1

G. Stephenson, Charles R. Yang, S. Mitchell, 2019, Journal of medicinal chemistry.

5-HT1A receptor antagonists reduce food intake and body weight by reducing total meals with no conditioned taste aversion

D. Sindelar, J. Shaw, J. Cramer, 2013, Pharmacology Biochemistry and Behavior.

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats

K. Cassidy, M. Mohutsky, J. Cramer, 2016, Drug Metabolism and Disposition.

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

D. McKinzie, Xia Li, J. Witkin, 2014, Neuropharmacology.

Bioisosteres of ethyl 8-ethynyl-6-(pyridin-2-yl)-4H-benzo[f]imidazo [1,5-a][1,4]diazepine-3-carboxylate (HZ-166) as novel alpha 2,3 selective potentiators of GABAA receptors: Improved bioavailability enhances anticonvulsant efficacy

D. Airey, J. Witkin, J. Fisher, 2018, Neuropharmacology.

Synthesis and Characterization of a Novel γ-Aminobutyric Acid Type A (GABAA) Receptor Ligand That Combines Outstanding Metabolic Stability, Pharmacokinetics, and Anxiolytic Efficacy.

J. Witkin, L. Arnold, J. Cramer, 2016, Journal of medicinal chemistry.

Effects of Corticotropin-Releasing Factor 1 Receptor Antagonism on the Hypothalamic-Pituitary-Adrenal Axis of Rodents

D. Gehlert, J. Cramer, S. Morin, 2012, Journal of Pharmacology and Experimental Therapeutics.

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis

Todd R. Wiernicki, Charles R. Yang, T. Suter, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Bioorganic & Medicinal Chemistry 22 (2014) 6965–6979

P. Hipskind, J. Sacchettini, T. Ioerger, 2014 .

Effects of DPTQ, a novel positive allosteric modulator of the dopamine D1 receptor, on spontaneous eye blink rate and spatial working memory in the nonhuman primate

Graham V. Williams, S. Castner, H. Marston, 2023, Psychopharmacology.

Structure-Based Design of Active-Site-Directed, Highly Potent, Selective, and Orally Bioavailable Low-Molecular-Weight Protein Tyrosine Phosphatase Inhibitors.

N. Noinaj, Zhon-Yin Zhang, M. Michael, 2022, Journal of medicinal chemistry.